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We investigated the changes in GH-IGF-I axis in
non-obese diabetic (NOD)-mice, a model of insulin-
dependent diabetes mellitus. Diabetic female NOD
mice and their age- and sex-matched controls were
sacrificed at 4, 14, 21 and 30 days (30d DM) after the
onset of glycosuria. Serum GH levels increased and
serum IGF-I levels decreased in the 30d DM group
(182 +_. 32% and 45 -" 24% of age-matched controls
respectively, p < 0.05). Another group (30d DM + I)
was given SC insulin, and its serum IGF-I levels
remained decreased. Liver GH receptor (GHR) and
GH binding protein (GHBP) mRNA levels, as well
as liver membrane GH binding assays were deeply
decreased in the 30d DM group in comparison to
controls. GHR message and binding capacity re-
mained decreased in the 30d DM + I group. Renal
GHR mRNA was decreased at 21d DM but not at
14d DM, whereas GHBP mRNA remained un-
changed throughout the experiment. In conclusion,
increased serum GH levels are documented in NOD
diabetic mice, similarly to the changes described in
humans. The decrease in GHR levels and decreased
serum IGF-I in spite of increased circulating GH
suggest a state of GH resistance.
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INTRODUCTION
IDDM is accompanied by long-term complica-
tions, including nephropathy, retinopathy, neu-
ropathy and advanced atherosclerosis (Deckert
et al., 1978). The appearance of these complica-
tions, mainly nephropathy, increases the relative
mortality of IDDM patients by 100 times that
of the background population (Borch-Johnsen
et al., 1985). Growth hormone (GH) and insulin-
like growth factors (IGFs) may participate in
the development of diabetic kidney disease
(Flyvbjerg et al., 1992, 1989; Bach and Jerums,
1990; Phillip et al., 1994; Werner et al., 1990), as
well as other diabetic complications (Holly et al.,
1988; Houssay, 1936).
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The classical endocrine effect of pituitary-
secreted GH is the induction of liver IGF-I
production and secretion. This effect is mediated
via activation of the specific GH receptor (GHR),
which is extensively distributed in many tissues
(Chin et al., 1992). Its binding to GH activates a
signal transduction pathway (Cunningham et al.,
1991), which leads to increased transcription of
several early response genes (Gronowski and
Rotwein, 1994). Therefore it is possible that GH
exerts effects on target tissues which are inde-
pendent of IGF-I. In addition, diabetic children
and adolescents may not grow well (Murata
et al., 1994; Phillips and Orawski, 1977). This
growth retardation may be due to GH resist-
ance (English et al., 1993).
Experimental diabetes in rats using strepto-
zotocin (STZ) is characterized by suppressed cir-
culating levels of GH (Tannenbaum, 1981). This
is contrary to what has been described in hu-
mans (Blankestijn et al., 1993; Press et al., 1984;
Hayford et al., 1980). In addition, typical diabetic
glomerulosclerosis associated with increas-
ing azotemia does not develop, even in long-
term follow-up models. STZ may also induce
tumoral growth in the kidney, and fl-cell rege-
neration may appear (Horton et al., 1997; Chieco
et al., 1993). In contrast, the non-obese diabetic
(NOD)-mouse model may resemble human dia-
betic nephropathy more closely (Velasquez et al.,
1990). The NOD-mice develop hypoinsulinemia
secondary to autoimmune destruction of pan-
creatic fl-cells at an age of between 100 and
200 days (Tochino, 1984), in association with in-
sulitis and autoantibody production (Wicker
et al., 1986). As in humans, NOD mice develop
proteinuria and significant glomerular lesions,
including a prompt increase in glomerular sur-
face area and an increase in mesangial sclerosis
(Doi et al., 1990).
No data are available on serum GH levels in
NOD mice and their influence on liver IGF-I
secretion. In the present study we evaluated the
changes in serum GH and IGF-I, and analyzed
the expression and activity of liver and kidney
GHR and GHBP in NOD mice, up to four weeks
after the appearance of diabetes.
MATERIALS AND METHODS
Animals
Twelve-week-old female NOD/Alt mice were
purchased from Jackson Laboratories (Bar
Harbor, ME, USA). Animal breeding complied
with the NIH Guide for the Care and Use of
Laboratory Animals. The cumulative incidence
of overt diabetes in these animals is over 50%
in females by 100 days. Animals were housed
in standard laboratory cages and fed ad libitum
normal mouse chow. Animals had free access
to unlimited supplies of tap water. The appear-
ance and persistence of glycosuria determined
the onset of diabetes. This was checked weekly
in all animals using chemstrips (Ketostix, Bayer-
Ames, UK). When the urine glucose test was
positive, tail capillary blood samples were
checked with Glucometer Elite (Bayer Diagnos-
tics, Puteaux Cedex, France). The normal range
(99% confidence level) of blood glucose levels
for NOD mice is from 3.0 to 9.9mmol/L. Dia-
betes was diagnosed when blood glucose levels
were above the normal range on two consecutive
days. The day that glycosuria was first noted
was considered as day 1 of diabetes. Diabetic
mice were sacrificed 4 (group 4d DM), 14 (14d
DM), 21 (21d DM) and 30 (30d DM) days after
the onset of diabetes. Normoglycemic (as deter-
mined by normal blood glucose levels at the day
of sacrifice) age-matched femaleNOD mice were
used as controls (group C). Another group of
diabetic NOD mice was treated with SC injec-
tions of Ultralente human insulin (Novo Nordisk,
Denmark) on an every other day basis from the
beginning of glycosuria. Insulin dosage was gra-
dually increased to 4 units per injection, which
only kept serum glucose levels below 25 mmol/LGH-IGF-I AXIS CHANGES IN NOD MICE 11
(450 mg/dl) and animals non-ketotic. This group
was sacrificed after 30 days of diabetes (group
30d DM + I). Mice were sacrificed by decapita-
tion. Trunk blood was collected and serum
was separated and frozen in -20C to measure
later GH and IGF-I levels. Liver and kidney
tissue were removed carefully and immediately
frozen in liquid nitrogen and then transferred to
-70C.
Determination of Serum IGF-I
Serum IGF-I was measured after extraction
with acid-methanol (30tl serum and 7501
acid-methanol). The mixture was incubated for
2 hours at room temperature, centrifuged and
25btl of the supernatant was diluted 1:200
before analysis. Serum IGF-I was measured by
radioimmunoassay (RIA) using a polyclonal
rabbit antibody (Nichols Institute Diagnostics,
San Capistrano, Calif., USA) and recombinant
human IGF-I as standard (Amersham Interna-
tional, Amersham, Bucks, UK). Mono-iodinated
IGF-I (125I-(tyrS1)-IGF-I) was obtained from
Novo-Nordisk A/S, Bagsvaerd, Denmark. When
exposing the serum extract to Western ligand
blot (WLB), no IGFBPs could be identified.
Furthermore, semilog linearity of biosynthetic
IGF-I and serum extracts was seen, indicating
antigen similarity and that no IGFBPs interfer-
ed in the RIA. Intra- and interassay variability
was below 5 and 10%, respectively.
Serum GH Determination
SerumGH was measured by radioimmunoassay
(RIA) using specific polyclonal rabbit anti-rat-
GH (rGH) antibody and rGH as standard.
Semilog linearity of mouse serum and rGH (in
the standard) was found at multiple dilutions,
indicating antigen similarity between mouse GH
and rGH. The ingredients including 125I-rGH
were obtained from Amersham (Amersham
International, Bucks, UK). Intra- and interassay
coefficients of variation were less than 5% and
10%. However, in the present study all samples
were run in one assay.
mRNA Analysis
Frozen tissues in 4M guanidinium isothiocya-
hate were loaded on cesium chloride and total
RNA was isolated following the methods as
described elsewhere (Phillip et al., 1994). The
precipitated RNA was resuspended in sterile
H20 and quantitated by absorbency at 260 nm.
The integrity equivalent loading of total RNA
was assessed by visual inspection of the ethi-
dium bromide-stained 28S and 18S RNA bands
after electrophoresis through 1.25%/2.2M for-
maldehyde gels. Liver and kidney GHR and
GHBP mRNA levels were determined using
Northern blot analysis. Twenty tg of total RNA
were electrophoresed on 1.3% agarose/2.2M
formaldehyde gel in 3-MOPS buffer. The RNA
was then transferred onto MagnaGraph (MSI,
Westboro, MA, USA) nylon membrane and was
crosslinked to the membrane with a UV cross-
linker (Hoefer Scientific Instr., San Francisco,
CA, USA). A 4.4 kb transcript encoding the GHR
and a 1.2 kb transcript encoding the GHBP were
detected using a 964 bp fragment of the GHR
cDNA, comprising the extracellular domain, the
putative transmembrane region, and the short
section of the intracellular domain (a gift of L.
Mathews). This construct was linearized using
BamH1 and radiolabelled with c-32pdCTP (3000
Ci/mmol; Amersham) by a random primed
DNA labelling kit (Boerhinger Manheim,
GmbH, Germany). RNA hybridization was
performed in a hybridization oven (Micro-4
Hybaid Ltd, UK) at 65C for 20 hours in
hybridization solution (0.2 mM Na2HPO4, pH
7.2; 7% vol./vol. SDS; 1% wt/vol. BSA; and
lmM EDTA). The washings were done in 0.4X
SSC and 0.1% SDS at 65C. Gels were exposed to
Kodak X-Omat AR film (Eastern Kodak, Ro-
chester, NY, USA) at -70C with 2 intensifying12 D. LANDAU et al.
screens. The autoradiograms were quantitated
using a phosphorimager (Imagequant, Molecu-
lar Dynamics, Sunnyvale, CA, USA).
Receptor Preparation
Receptor preparation was carried out as pre-
viously described (Tushina and Friesen, 1973).
Liver was homogenized in 0.25% sucrose solu-
tion, centrifuged at 10,000g for 10 minutes
followed by further centrifugation of the super-
natant at 100,000 g for 90 minutes, which yield-
ed the microsomal pellet. The pellet was then
resuspended in 25mM Tris-HC1/10 mM MgC12
buffer (pH 7.4). The quantity of microsomal pro-
teins was measured by the method of Lowry
et al. (1951), using human serum albumin as a
standard. The microsomal fraction was frozen
and thawed 3 times and then kept frozen until
used for the binding studies (Bergeron et al.,
1978). The human somatotropin (hGH, 20 I.U./
mg protein) used for iodination and as standard
was generously donated by Kabi Diagnostica,
Stockholm, Sweden. Na 125I (NEZ-033A), carrier
free, was purchased from NEN Life Science
Products (Boston, USA). Iodination of hGH and
binding assays were performed as previously
described by us (Eshet et al., 1985). Iodinated
preparations were used no more than 2 weeks
after iodination. One hundred tl of labelled
hGH (25,000cpm) were incubated with the
liver microsomal pellet fraction and 100 tl of
various concentrations of unlabelled hGH in
25mM Tris-HC1/10mM MgC12 buffer (pH 7.4)
containing 0.1% bovine serum albumin in a final
volume of 0.5ml. This was incubated at 4C
with constant shaking for 48 hours and the in-
cubation was terminated by adding 2ml ice-cold
0.1% bovine serum albumin/Tris/Mg buffer as
noted above. Receptor-bound and free radioacti-
vity was separated by centrifugation at 2000g
for 30 minutes at 4C. Radioactivity was meas-
ured in an autogamma scintillation spectrometer.
Parallel incubations were made in the pres-
ence of excess (5tg/ml) unlabelled hormone.
Specific binding is the difference between radio-
activity bound in the absence (TB, total binding)
and the presence (NSB, non-specific binding)
of excess unlabelled hormone and is expressed
as a percentage of the total radioactivity in the
incubation. The capacity and the dissociation
constant of liver GH receptor were evaluated
using the Scatchard plot analysis.
Statistical Analysis
Statistical differences between groups were de-
termined by one-way ANOVA for non-repeated
measures. Dunnett’s test was used to find the
source of significance in relation to controls. P
values equal or less than 0.05 were considered
significant. Values are expressed as mean 4-SEM
unless otherwise stated.
RESULTS
The mice used in this study (n 6 in each group)
became diabetic at a mean age of 104 4-15 days.
Control mice had a mean age of 119 4-6 days
when sacrificed (p= NS). Diabetic mice weight
was lower than controls (23 4- 0.6 and 18.3 4- 0.8
grams in the 4d DM and 30d DM groups
respectively, vs. 25.34-0.7 grams in control
animals; P < 0.01). The weight of the 30d DM+ I
group (diabetic animals treated with insulin)
was also lower than controls (85.6 4- 2% of con-
trol, P < 0.01) but higher than the 30d DM ani-
mals (21.7 4- 0.61 vs. 18.3 4- 0.82 grams; P < 0.01)
(Fig. la).
Serum IGF-I levels did not change during the
first two weeks of diabetes, but a significant
decrease was observed after 4 weeks in diabetic
animals (158 4- 38 vs. 351 4-15 ng/ml in controls,
p<0.05). Serum IGF-I remained low in the
30d DM+I group (404-9.9% of controls, p<
0.05) (Fig. lb). Serum GH levels were elevated
in the 30d DM group in comparison to controls
(51 4- 9 vs. 28 4- 2 ng/ml respectively; p < 0.01)
(Fig. 1). In the 30d DM+ I such elevation wasGH-IGF-I AXIS CHANGES IN NOD MICE 13
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FIGURE 1 (a) Animal weight (BW, in grams), (b) serum
IGF-I (in ng/ml) and (c) serum GH (in ng/ml) levels inNOD
mice, in controls, 4 and 30 days diabetic (DM) mice.
30DM+ I: diabetic mice treated for 30 days with 4 IU of
ultralente insulin every other day. *p < 0.01 vs. control.
not observed (Fig. lc). Data on serum IGF-I
levels have been previously described by us
(Segev et al., 1997).
Steady state liver GHR mRNA levels were
decreased in diabetic animals already at 4
days (47 4-10% of control, p=0.004) and per-
sisted over one month of diabetes (33 4- 9% of
60-
, 40-
;:::::a.
(C) Control 4d DM 30d DM
FIGURE (Continued).
30d DM+I
age-matched control, p < 0.001). The GHR mes-
sage remained decreased in the 30d DM +I
group: mRNA levels remained as low as
20 4-2% of non-diabetic animals (p < 0.0001).
Liver GHBP mRNA followed the same pattern
as GHR mRNA, and its levels decreased to
67 4-4% and 30 4-4% of controls at 4 and 30 days
of diabetes respectively (p < 0.001) (Fig. 2).
Renal GHR and GHBP mRNA levels showed
complex changes in 2 and 3-week non-treated
diabetic mice in comparison to controls (Fig. 3).
GHBP mRNA remained unchanged in these
two time points. Renal GHR mRNA was not
significantly decreased at two weeks of DM
(77 4- 5.4% of age-matched controls; p NS), but
the receptor message was significantly de-
creased at 3 weeks of DM (30 4-10% of control;
p <0.01).
GHR binding assays performed on liver
membranes demonstrated a linear configura-
tion. We found a decrease in the binding
capacity of the receptor in diabetic mice after
one month of diabetes in comparison to controls
(118 4- 26 vs. 475 4- 63 fmol receptor/g protein;
p<0.0001) whereas receptor affinity remained
unchanged (0.42 4- 0.12 vs. 0.28 4- 0.03 nmol/L;14 D. LANDAU et al.
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FIGURE 2 (a) Northern blot analysis of liver (20 ktg) total RNA of control, 4 days and 30 days diabetic (DM) NOD mice.
DM+ I: 30 day diabetic animals treated with 4 IU of ultralente insulin. The 4.4 kb and 1.2 kb bands corresponding to the GHR
and GHBP are shown on the left. Film was exposed for 96 hours at -70C with two intensifying screens. (b) Quantitation of
liver GHR and GHBP levels from the autoradigraph shown in Figure 2a, using a phosphorimager. The data are expressed as the
percentage of age-matched non-diabetic controls, n 5 rats in each group. *p < 0.05 vs. control.
p-NS). GHR binding capacity remained low
and unchanged in the 30d DM + I group (Fig. 4).
DISCUSSION
This study shows new evidence on the similar-
ity of the NOD model to human IDDM: as in
humans, increased circulating GH levels are
found in these hyperglycemic mice, a change
that is not modulated by insulin therapy. GH is
usually secreted in a pulsatile fashion, and a
single measurement of the serum GH may not
properly reflect GH levels. However, in the
control group GH has also been sampled in the
same way. In addition, the decapitation proce-
dure for blood sampling in our experiment has
been shown to be a significant stimulus for
GH secretion (Takahashi et al., 1971). Thus, the
results presented by us reflect a true increaseGH-IGF-I AXIS CHANGES IN NOD MICE 15
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FIGURE 3 Northern blot analysis of kidney GHR and GHBP: 20 tg total RNA of control, 14 and 21 day diabetic (DM) mice
were analyzed. Renal GHR and GHBP levels were quantitated using a phosphorimager. Data presented summarize 3 series of
experiments, repeated twice each. The data are expressed as the percentage of age-matched non-diabetic controls. *p < 0.001 vs.
control.
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FIGURE 4 Binding capacity of GH receptor sites in liver of NOD non-diabetic (control), in 4 days and 30 days diabetic (DM)
NOD mice and in 30 day diabetic animals treated with 4 IU of ultralente insulin (DM+I). n =6 in each group. *p<0.0001.16 D. LANDAU et al.
in serum GH levels in NOD diabetic mice. This
is in contrary to previous reports on the usual
model of animal IDDM, i.e., streptozotocin
injection. In this model decreased circulating
GH levels have been described, probably due
to inhibition of GH release from the pituitary
(Tannenbaum, 1981).
Increased GH action on target tissues may be
an important risk factor (independent of IGF-I)
for the development of diabetic complications,
such as nephropathy and retinopatliy. Where-
as transgenic mice for bovine-GH develop
advanced glomerulosclerosis and die of renal
failure, transgenic mice for a variant of GH
which antagonizes native GH effects (and causes
decreased somatic growth) are protected against
the development of nephropathy (Esposito
et al., 1996). Recently Doublier et al. (1997) pro-
vided an additional evidence for the importance
of a high GH-low IGF-I environment for the
development of glomerulosclerosis: transgenic
mice for IGFBP-1 that display such a hormonal
combination develop glomerulosclerosis. Doi
et al. (1990) have shown the natural history of
long-standing diabetes in NOD mice. In these
animals serum creatinine levels remain normal
even after 3 months of diabetes. However, they
develop progressive albuminuria and glomeru-
lar changes (such as mesangial expansion and
sclerosis) that are more similar to diabetic glo-
merulosclerosis. In the present study we show
that renal GHR mRNA decreases only after 3
weeks of diabetes, whereas GHBP mRNA levels
remain unchanged. On the other hand, liver
GHR and GHBP mRNA are profoundly de-
creased early after diabetes onset. GHRs are
upregulated in diabetic adipocytes, causing an
enhanced sensitivity to GH (Solomon et al.,
1990). Thus, GHR and GHBP may be differen-
tially regulated in IDDM.
Renal GH binding to kidney tissue is in-
creased in diabetic rats (Marshall et al., 1991). In
addition, renal GHBP is upregulated in a model
of long-term diabetes (Landau et al., 1998). No
change in renal GHR mRNA levels was seen in
that model. Kidney IGF-I protein is accumulated
in diabetic animals (Segev et al., 1997) together
with an increase in kidney IGFBP-1. Given the
increased circulating GH levels seen in this
model as well as in human disease, an increased
biological effect of GH on the kidney tissue
(including sclerosis) is possible. However, this
hypothesis will have to be further investigated
in future studies.
Stunted growth in children with IDDM is a
known clinical observation, even though in-
creased GH levels are known in human disease.
Since most of the growth promoting actions
of GH are mediated by (predominantly liver
originated) IGF-I action on bone, a GH insensi-
tivity would be a possible explanation. Such
insensitivity to GH could take place at the
receptor levels (Bornfelt et al., 1989) or in post-
receptor mechanisms (Maes et al., 1986). We
show in this study that circulating IGF-I levels
are decreased in diabetic mice. In a previous
study (Segev et al., 1997) we have shown that
this decrease in serum IGF-I is associated with
complex changes in the IGFBPs: IGFBP-3 (the
predominant carrier of IGF in the circulation)
and IGFBP-4 decreased whereas IGFBP-1 in-
creased. Analysis of GH binding to liver
membranes also showed a decreased receptor
binding capacity, with no change in affinity.
Previous studies have shown a decrease in liver
GHBP in diabetic states. Plasma concentrations
of GHBP are reduced in untreated sponta-
neously diabetic BB rats, with full normalization
during insulin administration (Massa et al.,
1993). A decrease in serum GHBP was found
in human patients with IDDM (Mercado et al.,
1992). Such reduced IGF-I secretion is associated
with low hepatic GHR levels that also normalize
during insulin treatment (Postel Vinay et al.,
1982).
A similar relationship between serum insulin
levels and serum GHBP was also shown in
humans (Kratzsch et al., 1996). We show here
that elevated serum GH and decreased serum
IGF-I levels are associated with a decreasedGH-IGF-I AXIS CHANGES IN NOD MICE 17
expression of liver GHR and GHBP mRNA and
GH binding. Insulin treatment did not fully
reverse these findings. Previous studies in rats
have raised the possibility of a cross binding
of hGH with the rat prolactin receptor (Postel
Vinay and Desbuquois, 1977). No data is avail-
able on hGH binding to prolactin receptor in
mice. In addition, our mRNA results support
our hypothesis that there is really a decrease
in GHR message in IDDM. Even though a
significant reduction in serum glucose was
achieved in our insulin-treated diabetic animals,
no tight control of the hyperglycemic state was
reached. Thus, it is possible that a much tighter
control of hyperglycemia would cause a reversal
of the changes in serum IGF-I and liver GHR
expression.
In summary, increased serum GH levels are
documented inNOD diabetic mice 4 weeks after
the appearance of glycosuria, similarly to the
changes described in humans. The decrease in
liver GHR levels and decreased serum IGF-I
suggest a state of GH resistance at this organ
level. This increase in circulating GH may affect
target organs for diabetic complications, such as
the kidney. Further studies are needed in order
to ascertain whether normalizing increased GH
levels can modulate those changes.
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